<html><head></head><body><h1>Lustra Cream</h1><p class="drug-subtitle"><b>Generic Name:</b> hydroquinone<br/>
<b>Dosage Form:</b> cream<br/></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Side Effects</li>
<li>Dosage</li>
<li><b class="nav-item here">Professional</b></li>
<li>Pregnancy</li>
<li>Breastfeeding</li>
<li class="nav-more">
More&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewBox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/body&gt;&lt;/html&gt;
</li>
</ul><p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.</p><ul>
<li>Description</li>
<li>Clinical Pharmacology</li>
<li>Indications and Usage</li>
<li>Dosage and Administration</li>
<li>Contraindications</li>
<li>Warnings</li>
<li>Precautions</li>
<li class="ddc-toggle-hidden">Adverse Reactions/Side Effects</li>
<li class="ddc-toggle-hidden">Overdosage</li>
<li class="ddc-toggle-hidden">How Supplied/Storage and Handling</li>
<li class="ddc-toggle-hidden">References</li>
</ul><p class="First"><span class="Bold">LUSTRA<span class="Sup">®</span></span></p><p><span class="Bold">(HYDROQUINONE CREAM USP, 4%)</span></p><p>The Complete Treatment for Dyschromia</p><p><span class="Bold">LUSTRA-AF<span class="Sup">®</span></span></p><p><span class="Bold">(HYDROQUINONE CREAM USP, 4%)</span></p><p>The Complete Treatment for Dyschromia</p><p><span class="Bold">Rx Only</span></p><p><span class="Bold">FOR EXTERNAL USE ONLY</span></p><p>The Lustra brand name has been discontinued in the U.S. If generic versions of this product have been approved by the FDA, there may be generic equivalents available.</p><h2>I. DESCRIPTION</h2><p class="First">Hydroquinone is 1,4-benzenediol. Hydroquinone is structurally related to monobenzone. Hydroquinone occurs as fine, white needles. The drug is freely soluble in water and in alcohol and has a pK<span class="Sub">a</span> of 9.96. Chemically, hydroquinone is designated as p-dihydroxybenzene; the empirical formula is C<span class="Sub">6</span>H<span class="Sub">6</span>O<span class="Sub">2</span>; molecular weight 110.1. The structural formula is:</p><p class="MultiMediaCaption">C<span class="Sub">6</span>H<span class="Sub">6</span>O<span class="Sub">2</span></p><h3>CONTENTS</h3><p class="First">Hydroquinone USP 4%.</p><p class="First">Alcohol, benzyl alcohol, butylated hydroxytoluene, carbomer 940, cetearyl alcohol (and) ceteareth-20, cetyl alcohol, cyclopentasiloxane (and) polysilicone-11, dimethiconol, disodium EDTA, fragrance, glycerin, glyceryl stearate (and) PEG-100 stearate, glycolic acid, hydrogenated lecithin, linoleic acid, magnesium 1-ascorbyl phosphate, phenoxyethanol, phenyl trimethicone, polyacrylamide (and) C13-14 isoparaffin (and) laureth 7, purified water, sodium metabisulfite, sodium citrate dihydrate, vitamin E acetate, vitamin E alcohol, triethanolamine.</p><p class="First">Alcohol, avobenzone, benzyl alcohol, butylated hydroxytoluene, carbomer 940, cetearyl alcohol (and) ceteareth-20, cetyl alcohol, cyclopentasiloxane (and) polysilicone-11, dimethiconol, disodium EDTA, fragrance, glycerin, glyceryl stearate (and) PEG-100 stearate, glycolic acid, hydrogenated lecithin, linoleic acid, magnesium 1-ascorbyl phosphate, octinoxate, phenoxyethanol, phenyl trimethicone, polyacrylamide (and) C13-14 isoparaffin (and) laureth 7, purified water, sodium metabisulfite, sodium citrate dihydrate, vitamin E acetate, vitamin E alcohol, triethanolamine.</p><h2>II. CLINICAL PHARMACOLOGY</h2><p class="First">Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3-(3,4-dihydroxyphenyl) alanine (dopa)<span class="Sup">1</span> and suppression of other melanocyte metabolic processes.<span class="Sup">2</span> Exposure to sunlight or ultraviolet light will cause repigmentation which may be prevented by the broad spectrum sunscreen agents contained in LUSTRA-AF<span class="Sup">®</span>.<span class="Sup">3</span></p><h2>III. INDICATIONS AND USAGE</h2><p class="First">LUSTRA<span class="Sup">®</span> and LUSTRA-AF<span class="Sup">®</span> are indicated for the gradual treatment of ultraviolet induced dyschromia and discoloration resulting from the use of oral contraceptives, pregnancy, hormone replacement therapy, or skin trauma.</p><h2>IV. DOSAGE AND ADMINISTRATION</h2><p class="First">LUSTRA<span class="Sup">®</span> or LUSTRA-AF<span class="Sup">®</span> should be applied to the affected areas twice daily, morning and before bedtime, or as directed by a physician. During and after the use of LUSTRA<span class="Sup">®</span> sun exposure should be limited, and a sunscreen agent or sun-protective clothing should be used to cover the treated areas, to prevent repigmentation. There is no recommended dosage for pediatric patients under 12 years of age except under the advice and supervision of a physician.</p><h2>V. CONTRAINDICATIONS</h2><p class="First">LUSTRA<span class="Sup">®</span> and LUSTRA-AF<span class="Sup">®</span> are contraindicated in any patient that has a prior history of hypersensitivity or allergic reaction to hydroquinone or any of the other ingredients. The safety of topical hydroquinone use during pregnancy or on children (12 years and under) has not been established.</p><h2>VI. WARNINGS</h2><h2>VII. PRECAUTIONS</h2><p class="First">SEE <span class="Bold">WARNINGS</span></p><h2>VIII. ADVERSE REACTIONS</h2><p class="First">No systemic reactions have been reported. Occasional cutaneous hypersensitivity (localized contact dermatitis) may occur, in which case the medication should be discontinued and the physician notified immediately.</p><h2>IX. OVERDOSAGE</h2><p class="First">There have been no systemic reactions reported from the use of topical hydroquinone. However, treatment should be limited to relatively small areas of the body at one time, since some patients experience a transient skin reddening and a mild burning sensation which does not preclude treatment.</p><h2>X. HOW SUPPLIED</h2><p class="First">LUSTRA<span class="Sup">®</span> (Hydroquinone Cream USP, 4%) is available as follows:</p><p>LUSTRA-AF<span class="Sup">®</span> (Hydroquinone Cream USP, 4%) is available as follows:</p><h2>REFERENCES</h2><p class="First"><span class="Bold">Store at 20°-25°C (68°-77°F)</span> [see USP Controlled Room Temperature].</p><p class="First">Covered by US Patent 5,932,612.</p><p>Mfd. by: Taro Pharmaceuticals Inc.<br/>
Brampton, Ontario, Canada L6T 1C1</p><p>Dist. by: <span class="Bold">TaroPharma</span><br/>
a division of Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532</p><p>Made in Canada</p><p>LUSTRA<span class="Sup">®</span>, LUSTRA-AF<span class="Sup">®</span> and TaroPharma<span class="Sup">®</span> are registered trademarks of<br/>
Taro Pharmaceuticals U.S.A., Inc.</p><p>Revised: October, 2011</p><p>PK-4967-3<br/>
111</p><h2>PRINCIPAL DISPLAY PANEL - 56.8 g Tube Carton</h2><p class="First"><span class="Bold">NDC 51672-1326-3</span></p><p><span class="Bold">RX ONLY</span></p><p><span class="Bold">LUSTRA</span><span class="Sup">®</span></p><p><span class="Bold">(HYDROQUINONE CREAM USP, 4%)</span></p><p><span class="Bold">NET WT. 2 oz (56.8 g)</span></p><h2>PRINCIPAL DISPLAY PANEL - 56.8 g Tube Carton</h2><p class="First"><span class="Bold">NDC 51672-1327-3</span></p><p><span class="Bold">RX ONLY</span></p><p><span class="Bold">LUSTRA-AF</span><span class="Sup">®</span></p><p><span class="Bold">(HYDROQUINONE CREAM USP, 4%)</span></p><p><span class="Bold">NET WT. 2 oz (56.8 g)</span></p><h2>More about Lustra (hydroquinone topical)</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug class: topical depigmenting agents</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Hydroquinone Time Release Cream &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Other Formulations</h3><ul class="more-resources-list more-resources-list-formulations">
<li>Lustra-Ultra</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Dermatological Disorders</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>